# Inhibition of the Renin Angiotensin System With Losartan in Patients With Hypertrophic Cardiomyopathy

Study · id `cardio:ct-nct01447654` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01447654](<https://clinicaltrials.gov/study/NCT01447654>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01447654

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 130 participants.

## Technical summary

Registry record NCT01447654. Randomized; quadruple masking; primary purpose treatment. Start 2011-11 (registry gives no type); primary completion 2014-06 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 130 participants (enrolled count; ClinicalTrials.gov record NCT01447654, source copy `cardio:ctgov-nct01447654-2014-07-09`, retrieved 2026-10-31)
- Start date: 2011-11 (registry gives no type) (ClinicalTrials.gov record NCT01447654, source copy `cardio:ctgov-nct01447654-2014-07-09`, retrieved 2026-10-31)
- Primary completion: 2014-06 (actual) (ClinicalTrials.gov record NCT01447654, source copy `cardio:ctgov-nct01447654-2014-07-09`, retrieved 2026-10-31)
- Completion: 2014-06 (actual) (ClinicalTrials.gov record NCT01447654, source copy `cardio:ctgov-nct01447654-2014-07-09`, retrieved 2026-10-31)
- Countries: Denmark (ClinicalTrials.gov record NCT01447654, source copy `cardio:ctgov-nct01447654-2014-07-09`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01447654-2014-07-09`, retrieved 2026-10-31)

## The registry's words

- Brief title: Inhibition of the Renin Angiotensin System With Losartan in Patients With Hypertrophic Cardiomyopathy
- Acronym: INHERIT
- Condition: Hypertrophic Cardiomyopathy
- Intervention (Drug): Losartan
- Intervention (Drug): Placebo
- Lead sponsor: Henning Bundgaard
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry condition terms include this condition: Hypertrophic cardiomyopathy (`cardio:hypertrophic-cardiomyopathy`)
- Registry intervention name matches this record: Losartan (`cardio:losartan`)
- Registry intervention is a member of this class by a sourced record link: Angiotensin receptor blockers (ARBs) (`cardio:angiotensin-receptor-blockers-arbs`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial (`cardio:pubmed-25533774`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Functional effects of losartan in hypertrophic cardiomyopathy-a randomised clinical trial (`cardio:pubmed-26661322`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 0d1fe39af3fc1ee66eec444da905d827faed8ffc69831f71a9152889563a0394
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
